Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
This study aims to explore the potential of RDN as a therapy for HFpEF in a Prospective, Multicenter, Randomized, Blinded, Sham-controlled Study.
| Condition(s) | Heart Failure With Preserved Ejection Fraction, Renal Denervation |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to explore the potential of RDN as a therapy for HFpEF in a Prospective, Multicenter, Randomized, Blinded, Sham-controlled Study. |
| Who can participate | Inclusion Criteria: 1. signs or symptoms of heart failure; 2. normal or mildly abnormal systolic LV function (LVEF ≥ 50%); 3. evidence of diastolic LV dysfunction. 4. Individual should fulfill the diagnostic WHO criteria for hypertension: SBP \> 140 mmHg and/or DBP \> 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (\< 140/90mmHg by 24 hour ambulatory BP measurement). 5. Individual is adhering to a stable drug regimen HFNEF, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months. Exclusion Criteria: 1. Known secondary cause of hypertension 2. Anatomy not eligible for renal |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Lead sponsor | Xinjiang Medical University |
| Locations | Ürümqi, Xinjiang, China |
| Start date | 2023-09-01 |
| NCT ID | NCT05715697 |
| Official listing | https://clinicaltrials.gov/study/NCT05715697 |